Comparative Pharmacology
Head-to-head clinical analysis: U CORT versus UTICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: U CORT versus UTICORT.
U-CORT vs UTICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
U-CORT (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and subsequent anti-inflammatory, immunosuppressive, and metabolic effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production and immune cell migration.
Uticort (betamethasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
U-CORT (hydrocortisone) 100 mg intravenous bolus, followed by 100 mg intravenous every 8 hours for 48 hours, then taper as clinically indicated.
Topical: Apply a thin film to affected area twice daily. Maximum 50 g per week. For short-term use only (≤2 weeks).
None Documented
None Documented
Terminal half-life approximately 1.6-2.2 hours; clinically used as short-acting topical corticosteroid.
Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 6-12 hours in hepatic impairment.
Primarily hepatic metabolism; inactive metabolites excreted renally (60-70%) and biliary/fecal (20-30%).
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% via enterohepatic circulation.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid